CPhI Online

PCI Pharma Services announces Bellwyck acquisition

11 Feb 2020

PCI Pharma Services has bought Toronto-based packaging and labelling specialist Bellwyck Pharma Services, adding four GMP-compliant facilities in the US, Germany and Canada to its global network, the CDMO announced Tuesday.

Bellwyck’s supply chain offering includes clinical trial packaging, labeling and logistics for Phase I-IV studies and commercial packaging.

“We are particularly excited that this acquisition will expand our clinical business worldwide and provide our clients with access to sites in continental Europe and Canada, in addition to our existing facilities,” said Salim Haffar, chief executive officer, PCI Pharma Services.

With the addition of Bellwyck, PCI will now feature 25 GMP facilities across North America, Europe, and Asia-Pacific, employing over 3,700 people.

The Bellwyck acquisition marks PCI’s third acquisition outside of the US in three years.

Related Categories